Regeneron to Report Fourth Quarter and Full Year 2024 Results

TARRYTOWN, N.Y., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced its plans to release its financial and operating results for the fourth quarter and full year of 2024 on Tuesday, February 4, 2025. This announcement will be made before U.S. financial markets open for the day.

Conference Call Details

The company will also hold a conference call and a simultaneous webcast at 8:30 AM Eastern Time on that day. Investors and interested parties can listen to the conference call live through a webcast available on the 'Investors and Media' section of Regeneron’s website at https://investor.regeneron.com.

For those wishing to join via telephone, participants must register in advance using a provided link. After registration, they will receive a confirmation email that includes details about how to dial in for the call, along with a unique passcode and registrant ID necessary for accessing the discussion. A recording and transcript of the conference call will be made available on the company's website for at least 30 days following the event.

About Regeneron Pharmaceuticals

Regeneron (NASDAQ: REGN) is a top-tier biotechnology firm committed to discovering and creating innovative medicines for critical health issues. Founded by physician-scientists, Regeneron excels at transforming scientific research into practical medical solutions. The company's various treatments and product candidates target a range of serious medical conditions, including eye diseases, allergies, cancer, heart diseases, neurological disorders, and rare diseases.

Employing its proprietary drug development technologies such as VelociSuite^®, Regeneron successfully produces optimized fully human antibodies and new classes of bispecific antibodies. Additionally, through the Regeneron Genetics Center^®, the company utilizes data-driven insights and pioneering genetic platforms to discover innovative therapeutic targets and strategies for potential disease cures.

For further information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook, or Twitter.

Regeneron, Conference, Results